10-K: Corteva Reports Strong 2025 Growth, Plans Dual Spin-Off

Corteva, Inc. reported significant financial improvements in 2025, including a 3% net sales increase and a 14% rise in operating EBITDA, while announcing plans to separate its Seed and Crop Protection businesses into two independent public companies by late 2026.

Summary

• Net sales for 2025 increased by 3% to $17,401 million, driven by a 1% price increase and a 3% volume increase, partially offset by a 1% unfavorable currency impact.
• Operating EBITDA grew by 14% to $3,848 million in 2025, up from $3,376 million in 2024, primarily due to volume growth, favorable Seed price and product mix, and cost/productivity benefits.
• Income from continuing operations after income taxes rose by 39.5% to $1,204 million in 2025, compared to $863 million in 2024.
• Diluted earnings per share from continuing operations increased to $1.75 in 2025 from $1.22 in 2024.
• The company returned approximately $1.5 billion to shareholders in 2025 through share repurchases and common stock dividends.
• The quarterly common stock dividend was increased by approximately 6% from $0.17 to $0.18 per share, approved on July 29, 2025.
• Corteva announced its intent on October 1, 2025, to separate its Seed and Crop Protection businesses into two standalone, publicly traded companies via a tax-free spin-off, expected to be substantially complete by the end of 2026.
• The Crop Protection Operations Strategy Restructuring Program incurred $150 million in charges in 2025, contributing to $611 million inception-to-date, with expected run-rate savings of $180 million by 2027.
• Free Cash Flow significantly increased by 68.7% to $2,866 million in 2025 from $1,699 million in 2024.
• The company resolved outstanding litigation with Bayer in January 2026, agreeing to a $610 million payment and dropping AAD-1 patent claims, while terminating certain cross-license agreements and establishing new cotton licensing arrangements.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive report, driven by robust financial performance across key metrics and a clear strategic direction with the announced spin-off, despite ongoing litigation and regulatory challenges.

Positives

• Net sales increased by 3% in 2025, demonstrating continued growth in the agriculture market.
• Operating EBITDA saw a robust 14% increase, reflecting strong operational performance and cost management.
• Income from continuing operations after income taxes surged by nearly 40%, indicating improved profitability.
• Diluted EPS from continuing operations rose significantly, enhancing shareholder value.
• The company returned approximately $1.5 billion to shareholders through dividends and share repurchases, including a 6% dividend increase.
• Free Cash Flow experienced substantial growth of 68.7%, highlighting strong cash generation capabilities.
• The Seed segment's net sales grew by 4% and operating EBITDA by 19%, with a 340 basis point margin improvement, driven by demand for top technology and increased out-licensing income.
• The Crop Protection segment's net sales increased by 2% and operating EBITDA by 6%, with a 70 basis point margin improvement, benefiting from raw material deflation, productivity savings, and new product demand.
• Resolution of Bayer litigation eliminates uncertainty and allows for new cotton licensing arrangements, supporting product out-licensing growth.
• The Crop Protection Operations Strategy Restructuring Program is expected to generate $180 million in run-rate savings by 2027.

Negatives

• Unfavorable currency impacts reduced net sales by 1% in 2025, led by the Turkish Lira and Canadian Dollar.
• Crop Protection pricing declined by 2% in 2025, primarily due to market dynamics in Latin America.
• Other income (expense) net showed a higher expense of $(570) million in 2025 compared to $(300) million in 2024, driven by litigation resolution costs.
• A $132 million charge was recorded in 2025 for a valuation allowance against the net deferred tax asset position of a legal entity in Brazil (Crop Protection business).
• Income (loss) from discontinued operations after income taxes resulted in a $(99) million charge in 2025, primarily due to PFAS environmental remediation activities and litigation charges related to the NJ Statewide Settlement.
• Increased R&D expense by $72 million in 2025, driven by higher employee compensation, contractor costs, and field/lab/facilities costs.
• Selling, General and Administrative (SG&A) expenses increased by $296 million in 2025, mainly due to higher commissions, variable compensation, bad debt expense, legal support fees, and personnel/IT costs.
• The company faces ongoing significant litigation, including antitrust lawsuits from the FTC and state attorneys general, and numerous PFAS-related claims, which could result in substantial liabilities.

Risks

• Inability to obtain or maintain necessary regulatory approvals for seed and crop protection products, leading to restricted sales and reduced R&D returns.
• Public understanding and acceptance of biotechnology and agricultural products affecting regulatory approvals, market acceptance, and potential litigation.
• Intensifying competition in the global agriculture market, including from generic crop protection chemicals and regional seed companies, leading to price pressures.
• Changes in agricultural and related government policies, including reduced subsidies, impacting farmer purchasing power and operating results.
• Costs of complying with evolving environmental, health, and safety regulations, including those related to PFAS, potentially leading to significant unanticipated costs or liabilities.
• Climate change and unpredictable seasonal/weather factors affecting seed production, crop protection demand, supply chains, and overall sales and earnings.
• Disruptions in the global economy due to geopolitical and military conflicts (e.g., Russia-Ukraine, China-Taiwan), potentially causing cyberattacks, supply chain disruptions, and foreign exchange volatility.
• Volatility in input costs (raw materials, production costs) impacting operating results if not fully offset by price increases or productivity improvements.
• Risks associated with international operations, including foreign currency fluctuations, inflation, political instability, and trade restrictions.
• Industrial espionage and other disruptions to supply chain, information technology, or network systems, including cyberattacks, potentially leading to business disruptions, loss of intellectual property, and legal claims.
• Environmental, litigation, and other commitments and contingencies, including substantial costs and liabilities from PFOA/PFAS lawsuits and other legal proceedings.
• Dependence on third parties for raw materials, biotechnology trait licenses, and commercialization, with potential negative impacts if obligations are not met or relationships are disrupted.
• Customers' inability to pay debts, especially in economic downturns or adverse growing conditions, affecting receivables and financial results.
• Failure to effectively manage acquisitions, divestitures, strategic investments, and restructurings, potentially leading to failure to achieve expected benefits or asset impairment charges.
• Impairment of liquidity or financial condition if unable to raise capital through capital markets or short-term debt borrowings.
• Increases in pension and other post-employment benefit plan funding obligations adversely affecting results of operations, liquidity, or financial condition.
• Negative impacts from global or regional health pandemics or epidemics on supply chains, operations, customer demand, and financial performance.
• Adverse effects on stock price, results of operations, and access to capital due to negative sentiment towards sustainability matters.
• Challenges in enforcing intellectual property rights or defending against claims by others, potentially impacting business, results, and financial condition.
• Adverse effects from the availability of counterfeit products on reputation, sales, and potential litigation.
• Restrictions under intellectual property cross-license agreements limiting ability to develop and commercialize certain products and services.
• Potential liabilities arising from the Corteva Separation and related transactions, including indemnification obligations and fraudulent conveyance claims.
• Risks related to the proposed separation of Seed and Crop Protection businesses, including potential delays, failure to achieve intended benefits, management distraction, increased costs, dis-synergies, and impact on stock value or tax-free status.

Future Outlook

Corteva aims to continue creating significant value by focusing on execution, delivering innovation faster through differentiated and sustainable solutions, and disciplined capital deployment. The company expects to complete the separation of its Seed and Crop Protection businesses into two standalone public companies in the second half of 2026, which is intended to be a tax-free spin-off. Capital expenditures for 2026 are estimated to be approximately $600 million. The company expects to evaluate discretionary contributions to its principal U.S. pension plan in 2026 and anticipates contributing approximately $40 million to other pension plans and $100 million to OPEB plans in 2026. For the first half of 2026, the company expects approximately $500 million in share repurchases under the 2024 Share Buyback Plan.

Management Comments

• Management believes its management team has the experience necessary to effectively execute its strategy and advance its product pipelines and technology.
• Management believes the company's strong employee base, along with its commitment to Corteva's core values, is a key element to the success of its business.
• Management believes the current assumptions and estimates utilized for goodwill impairment analyses are both reasonable and appropriate, concluding no goodwill impairment was necessary in 2025.
• Management believes its cash on hand, ability to generate cash from operations, and access to capital markets will be adequate to meet anticipated cash requirements.

Industry Context

StockSavvy.ai notes that Corteva's strong performance in 2025, particularly in its Seed segment, aligns with broader trends of increasing demand for advanced agricultural technologies and high-yield germplasm. The company's focus on gene editing, biofuels, and hybrid wheat positions it to capitalize on evolving farmer needs and sustainability drivers. The planned separation into two distinct entities reflects a strategic move seen across the chemical and agricultural sectors to unlock shareholder value by creating more focused businesses, potentially allowing each to better pursue tailored growth strategies and capital allocation. However, the industry continues to grapple with complex and evolving regulatory landscapes, particularly concerning GMOs and crop protection chemicals like PFAS, which pose significant legal and operational challenges for major players like Corteva. The resolution of the Bayer dispute, while costly, removes a significant overhang, potentially improving market clarity for its product portfolio. The ongoing FTC antitrust investigation highlights increasing regulatory scrutiny on market concentration within the agricultural input industry.

Comparison to Industry Standards

• Corteva's 3% net sales growth and 14% operating EBITDA increase in 2025 demonstrate strong performance, potentially outpacing some competitors in a market facing currency headwinds and competitive pricing in certain regions.
• The 340 basis point improvement in Seed segment operating EBITDA margin and 70 basis point improvement in Crop Protection segment operating EBITDA margin suggest effective cost management and favorable product mix, which could be above industry averages given the challenging market dynamics in Latin America.
• The company's commitment to returning $1.5 billion to shareholders through dividends and share repurchases, alongside a 6% dividend increase, indicates a strong financial position and shareholder-friendly capital allocation, comparable to leading companies in mature industries.
• The resolution of the Bayer litigation, involving a $610 million payment, is a significant event. While a substantial outflow, it removes a long-standing legal uncertainty, which could be viewed favorably compared to prolonged, unresolved disputes faced by other industry players like Bayer with its ongoing Roundup litigation.
• The planned spin-off of Seed and Crop Protection businesses mirrors strategic moves by other large diversified companies, such as DowDuPont's prior separations, aiming to create more agile and focused entities, potentially enhancing valuation multiples compared to a combined conglomerate structure.
• The extensive list of ongoing legal proceedings, particularly related to PFAS and antitrust, indicates a higher level of regulatory and litigation exposure compared to some smaller, more specialized agricultural companies, but is typical for a global leader with a long history and diverse product portfolio like Corteva.

Management Changes

Corporate Governance

Legal Proceedings

• Corteva filed a lawsuit against Inari Agriculture, Inc. in September 2023 for Plant Variety Protection infringement, indirect patent infringement, breach of contract, and civil conversion, with trial expected in H2 2026.
• Resolved outstanding litigation with Bayer in January 2026, involving a $610 million payment from Corteva, termination of certain cross-license agreements, and new cotton licensing arrangements.
• Facing an antitrust lawsuit filed by the FTC and ten state attorneys general in September 2022, alleging unfair competition and unlawful monopoly, with trials expected to begin in 2027.
• Subject to Lorsban lawsuits alleging personal injury from chlorpyrifos exposure, with an accrual established for estimated resolution of certain claims as of December 31, 2025.
• EIDP has residual liabilities from the 2004 Leach settlement and settled Ohio MDL PFOA personal injury cases for $59 million (Corteva's share $8 million paid).
• Involved in approximately 10,100 AFFF cases consolidated in a multi-district litigation (SC MDL) alleging personal injury and contamination, with the first bellwether trial expected in 2026.
• Participated in the Nationwide Water District Settlement, a binding agreement in principle from June 2023 to resolve PFAS drinking water claims for $1.185 billion, which became final in April 2024.
• Agreed to a proposed Judicial Consent Order with the State of New Jersey (NJ Statewide Settlement) in August 2025 to resolve legacy claims related to various substances and four former EIDP sites, involving aggregate cash payments of $875 million (NPV ~$500 million) over 25 years, with court approval expected in H1 2026.
• Facing complaints from four municipalities in the Netherlands (April 2021) alleging PFOA and GenX contamination, with the court ruling defendants liable for PFOA emissions in September 2023 and settlement discussions ongoing.
• Received a letter from the EPA in November 2024 asserting CERCLA claims related to alleged PFAS contamination from six historical and present DuPont and Chemours sites, with discussions ongoing.
• Participating in the NDEE's Voluntary Cleanup Program for the AltEn Facility in Nebraska, with an accrual established for Corteva's estimated voluntary contribution to remediation plans.
• Subject to a state court lawsuit by the California Department of Toxic Substances Control regarding a permit requirement for the Pittsburg plant's high purity water system, with discussions ongoing.

Related Party Transactions

• EIDP, a wholly-owned subsidiary of Corteva, is party to a Master In-House Banking Agreement with Corteva and certain consolidated subsidiaries to manage cash and liquidity needs.
• EIDP earned $38 million in interest income from Corteva, Inc. under the Master In-House Banking Agreement through Q3 2024; subsequently, borrowings are classified within EIDP's equity due to a change in repayment intent.
• EIDP declared cash dividends of $1,815 million in 2025 and $1,750 million in 2024 to Corteva, Inc., intended to fund Corteva's share repurchases and common stock dividends.
• EIDP repaid its related party revolving loan from Corteva, Inc. in the fourth quarter of 2023.
• EIDP had payables to Corteva, Inc. of $27 million at December 31, 2025, and $9 million at December 31, 2024, related to Corteva's indemnification liabilities to Dow and DuPont per the Separation Agreements.

Stakeholder Impact

• Shareholders benefit from increased dividends ($0.18 per share) and ongoing share repurchase programs ($1.5 billion returned in 2025), indicating a commitment to shareholder returns.
• Employees are supported by human capital management initiatives focusing on career development, training, safety, wellness, and inclusion, with nine global Employee Business Resource Groups.
• Customers are offered advanced seed and crop protection solutions, digital tools for optimizing yield and profitability, and financing programs, enhancing their productivity and profitability.
• Suppliers, particularly third-party growers, are integral to the Seed segment's supply chain, with Corteva providing training and planning tools.
• Creditors are assured by Corteva's commitment to a strong financial position and investment-grade credit rating, ensuring access to capital markets.
• Regulatory authorities are actively engaged through compliance with evolving environmental and product approval regulations, as well as ongoing legal proceedings related to antitrust and environmental matters.

Next Steps

• Complete the separation of Seed and Crop Protection businesses into two standalone, publicly traded companies in the second half of 2026.
• Continue to focus on execution, delivering top-tier technology, and market share gains in Seed trait out-licensing.
• Drive operational improvements focused on cost and productivity benefits, aiming for $180 million in run-rate savings by 2027 from the Crop Protection Operations Strategy Restructuring Program.
• Prioritize investment, organic and inorganic growth, and returning cash to shareholders.
• Evaluate discretionary contributions to the principal U.S. pension plan in 2026.
• Contribute approximately $40 million to other pension plans and $100 million to OPEB plans in 2026.
• Execute approximately $500 million in share repurchases under the 2024 Share Buyback Plan in the first half of 2026.
• Continue discussions with parties regarding the EPA CERCLA claims related to PFAS contamination.
• Await court approval for the NJ Statewide Settlement, expected during the first half of 2026.
• Prepare for the first bellwether personal injury trial in the AFFF SC MDL, expected in 2026.
• Prepare for trials in the FTC antitrust lawsuit, expected to begin in 2027.
• Prepare for the trial in the Inari disputes, expected to begin in the second half of 2026.

Key Dates

Recommendation

Corteva's 2025 results demonstrate strong operational execution, leading to significant increases in net sales, operating EBITDA, and free cash flow, alongside a commitment to shareholder returns through increased dividends and share repurchases. The planned spin-off of its Seed and Crop Protection businesses could unlock further value by creating more focused entities. However, the company faces substantial and complex litigation risks, particularly related to PFAS and antitrust, which could result in material liabilities and ongoing legal costs. While the resolution of the Bayer dispute is a positive, the sheer volume and nature of remaining legal challenges, coupled with the execution risks of a major corporate separation, warrant a cautious 'hold' stance. Investors should monitor the progress of the spin-off and the outcomes of key legal proceedings for clearer directional signals.

Keywords

Corteva, CTVA, Agriculture, Seed, Crop Protection, SEC Filing, 10-K, Financial Results, Operating EBITDA, Net Sales, EPS, Share Repurchase, Dividend Increase, Spin-off, Separation, Biotechnology, PFAS Litigation, Antitrust, Regulatory Risk, Sustainability, Innovation, Farm Bill, Geopolitical Risk, Supply Chain, Cybersecurity, Intellectual Property